8-K: Sono-Tek Reports Strong Q3 Margins, Record Backlog

Sono-Tek Corporation reported its seventh consecutive quarter of over $5 million in revenue, with gross margin expanding to 50% and record backlog of $12.3 million, despite a slight dip in net sales.

Summary

• Net sales for the third quarter ended November 30, 2025, were $5.0 million, a 4% decrease compared to $5.2 million in the prior-year period, marking the seventh consecutive quarter with revenue exceeding $5 million.
• Gross profit for the third quarter increased 7% year over year to $2.5 million, with gross margin expanding to 50% from 45% in the prior-year quarter.
• Operating income for the third quarter increased 61% to $319 thousand, reflecting improved gross margin and operating leverage.
• Net income for the third quarter increased 24% to $340 thousand, or $0.02 per diluted share, compared with $274 thousand, or $0.02 per diluted share, in the prior-year quarter.
• Net sales for the first nine months of fiscal year 2026 totaled $15.3 million, essentially flat year over year.
• Gross profit for the first nine months increased 6% to $7.8 million, with gross margin expanding to 51% from 48% in the prior-year period.
• Operating income for the first nine months increased 69% to $1.22 million.
• Net income for the first nine months increased 32% to $1.25 million, or $0.08 per diluted share, compared with $0.06 per diluted share in the prior-year period.
• The company ended the quarter with $11.7 million in cash, cash equivalents, and marketable securities and no outstanding debt.
• Total backlog reached a record $12.26 million, increasing 16% year over year and 9% sequentially, driven by continued customer order activity.
• Sono-Tek is reiterating its full fiscal year 2026 guidance, anticipating modest revenue growth, balancing market adjustments in clean energy with growing demand in the medical device market.

Sentiment

Score: 7

Explanation: Despite a slight revenue dip, strong gross margin expansion, significant net income growth, and record backlog indicate robust operational efficiency and future demand. The strategic shift to high-ASP systems and strength in the medical market are positive, offsetting anticipated challenges in alternative energy.

Positives

• Achieved seventh consecutive quarter of revenue over $5 million.
• Gross margin expanded to 50% in Q3 FY26 (up from 45%) and 51% year-to-date (up from 48%).
• Net income increased 24% in Q3 FY26 to $340 thousand and 32% year-to-date to $1.25 million.
• Operating income increased 61% in Q3 FY26 to $319 thousand and 69% year-to-date to $1.22 million.
• Total backlog reached a record $12.26 million, increasing 16% year over year and 9% sequentially.
• Strong balance sheet with $11.7 million in cash, cash equivalents, and marketable securities and no outstanding debt.
• In-Line Coating Systems revenue increased sharply by 2,177% in Q3 and 126% year-to-date, driven by high-ASP production systems.
• Medical sales increased 27% in Q3 and 37% year-to-date, supported by strong demand for various medical device coating systems.
• Electronics/Microelectronics sales increased 27% in Q3, reflecting increased fluxing demand and a semiconductor system shipment.
• Industrial sales increased 116% in Q3 due to a large advanced textile coating platform shipment.
• Fluxing Systems revenue increased 213% in Q3 and 80% year-to-date, primarily driven by stronger demand in Asia.
• U.S. & Canada sales increased 21% in Q3 and 3% year-to-date.

Negatives

• Net sales for Q3 FY26 declined 4% year over year to $5.0 million.
• Net sales for the first nine months of FY26 were essentially flat, declining 1% year over year.
• Multi-Axis Coating Systems revenue declined 53% in Q3 and 46% year-to-date due to reduced electrolysis-related demand following shifts in U.S. policy incentives.
• Alternative Energy sales declined 35% in Q3 due to reduced U.S. electrolysis activity following changes in government policy initiatives.
• Electronics/Microelectronics sales decreased 9% year-to-date following strong prior-year sales and customer timing shifts.
• Industrial sales decreased 26% year-to-date, influenced by a non-recurring large European glass coating order in the prior year.
• Asia Pacific sales declined 34% in Q3 following a strong prior year quarter.
• Latin America sales declined 50% in Q3 and 48% year-to-date due to slower fluxing activity in Mexico and non-recurrence of a prior-year orthopedic system shipment.
• EMEA sales decreased 26% in Q3 and 9% year-to-date primarily due to softer demand in the advanced energy market.

Risks

• General economic and business conditions, including political, regulatory, tax, competitive, and technological developments affecting operations or product demand.
• Inflationary and supply chain pressures.
• Maintaining the continued strength of sales to the medical device market.
• Continued private and public funding for the clean energy sector.
• Maintenance of order backlog.
• Evolving tariff policies.
• Timely development and market acceptance of new products and continued customer validation of coating technologies.
• Adequacy of financing.
• Capacity additions.
• Ability to enforce patents.
• Maintenance of operating leverage.
• Consummation of order proposals.
• Completion of large orders on schedule and on budget.
• Successful transition from primarily selling ultrasonic nozzles and components to a more complex business providing complete machine solutions and higher value subsystems.
• Realization of quarterly and annual revenues within the forecasted range of sales guidance.

Future Outlook

The company reiterates its full fiscal year 2026 guidance, anticipating modest revenue growth. This outlook balances market adjustments due to recent governmental deemphasis of clean energy initiatives and evolving tariff policies with positive demand growth in the medical device market.

Management Comments

• "We delivered another solid quarter marked by our seventh consecutive period of revenue above $5 million, continued profitability, and meaningful margin expansion." Dr. Christopher L. Coccio, Executive Chairman.
• "The improvement in gross margin reflects the success of our strategy to prioritize higher-ASP production systems and maintain disciplined cost management, even as certain end markets experience near-term variability." Dr. Christopher L. Coccio, Executive Chairman.
• "Reaching a record backlog is particularly encouraging and highlights sustained customer confidence in Sono-Tek's technology and long-term value proposition." Dr. Christopher L. Coccio, Executive Chairman.
• "Demand for our advanced ultrasonic coating platforms remains strong, led by continued momentum in the medical device market and increasing adoption of high-value production systems." Steve Harshbarger, CEO & President.
• "While U.S. alternative energy demand softened as anticipated due to policy-related timing shifts, growth across medical, electronics, and industrial applications more than offset this impact." Steve Harshbarger, CEO & President.
• "With a strong balance sheet, record backlog, and an expanding mix of high-ASP systems, we are well positioned to drive consistent performance and long-term growth." Steve Harshbarger, CEO & President.

Industry Context

Sono-Tek's performance reflects a strategic pivot towards high-value production systems and the robust medical device market, which is offsetting headwinds in the alternative energy sector. The softening U.S. alternative energy demand is attributed to shifts in government policy incentives and evolving tariff policies, a trend impacting several players in the clean energy space. The company's ability to leverage its technology across diverse applications like medical, electronics, and industrial, demonstrates resilience against sector-specific volatility.

Stakeholder Impact

• Shareholders: Positive impact due to increased net income, expanded gross margins, and record backlog, suggesting future revenue stability and profitability. The reiterated guidance for modest revenue growth provides a clear outlook.
• Customers: Continued confidence in Sono-Tek's technology, as evidenced by record backlog and strong demand for advanced ultrasonic coating platforms, particularly in medical devices and high-value production systems.
• Employees: Continued operational strength and growth in key markets may indicate job stability and potential for future expansion.

Key Dates

Recommendation

While Sono-Tek demonstrated strong operational performance with significant margin expansion and record backlog, the slight revenue decline in Q3 and flat year-to-date sales, coupled with headwinds in the alternative energy sector due to policy shifts, suggest a 'hold' position. The company's strategic focus on high-ASP systems and strength in the medical market are positive, but the overall revenue growth remains modest as per guidance. Investors should monitor the balance between growth in medical/high-ASP systems and the impact of policy changes on alternative energy.

Keywords

ultrasonic coating systems, medical devices, semiconductors, microelectronics, alternative energy, industrial manufacturing, financial results, gross margin, net income, backlog, SOTK, Sono-Tek